Progressive supranuclear palsy (PSP), first described by John Steele, Jerome Richardson, and Jerzy Olszewski in 1964, is a neurodegenerative disorder classified as a 4-repeat (4R) tauopathy. The disease is characterized neuropathologically by neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau protein, tufted astrocytes, and widespread neuronal loss with prominent gliosis. Understanding the neuropathology of PSP is essential for distinguishing it from other neurodegenerative diseases, particularly other 4R tauopathies like corticobasal degeneration (CBD), and for developing targeted therapeutics that address the underlying tau pathology. [1]
PSP affects approximately 5-7 per 100,000 individuals, making it the most common atypical parkinsonian syndrome after Parkinson's disease itself. The neuropathological hallmark is the accumulation of abnormal tau protein in neurons, astrocytes, and oligodendrocytes, leading to progressive neuronal dysfunction and death in specific brain regions responsible for motor control, balance, and cognitive function. [2]
The original description of PSP by Steele, Richardson, and Olszewski in 1964 established the clinical triad of vertical gaze palsy, pseudobulbar palsy, and parkinsonism with axial rigidity. This clinical syndrome, initially termed "progressive supranuclear ophthalmoplegia," was later renamed PSP to reflect the broader clinical spectrum beyond ocular motor involvement. The neuropathological correlates were subsequently characterized, establishing the diagnostic criteria that remain in use today. [3]
The tau protein is encoded by the MAPT (Microtubule-Associated Protein Tau) gene located on chromosome 17q21.31. It plays a critical role in microtubule stabilization, axonal transport, and neuronal polarity. The tau gene undergoes alternative splicing to produce six isoforms ranging from 352 to 441 amino acids, distinguished by the presence of 3 or 4 repeats (3R or 4R) of the microtubule-binding domain in the C-terminal half of the protein. [4]
Tau Isoforms:
In the normal adult human brain, approximately equal amounts of 3R and 4R tau isoforms are present. This balance is disrupted in various tauopathies, with PSP representing a "pure 4R tauopathy" where 4R tau predominates.
In PSP, tau protein undergoes abnormal post-translational modifications including hyperphosphorylation, truncation, and aggregation into paired helical filaments (PHFs) and straight filaments (SFs). These filaments form the insoluble inclusions that characterize the disease:
The tau protein in PSP is abnormally phosphorylated at numerous sites, including:
This hyperphosphorylation reduces tau's affinity for microtubules, leading to microtubule destabilization and axonal transport deficits, while simultaneously promoting aggregation into insoluble filaments. [5]
NFTs are the most well-characterized tau inclusion in PSP, composed of intracellular aggregates of hyperphosphorylated tau protein arranged as paired helical filaments. Unlike Alzheimer's disease where NFTs are predominantly cortical, in PSP they are especially abundant in subcortical structures:
NFT Distribution in PSP:
NFTs undergo stages of formation from pretangle neurons (diffuse cytoplasmic tau) to mature flame-shaped or globose tangles. The progression follows a characteristic pattern related to neuronal connectivity, supporting the concept of prion-like propagation. [6]
Tufted astrocytes represent one of the most pathognomonic neuropathological features of PSP, distinguishing it from other tauopathies including CBD. These are astrocytic inclusions characterized by tau-positive fibrils arranged in a dense, tufted pattern within astrocyte processes. They are most commonly observed in the striatum, motor cortex, and brainstem.
Key Features of Tufted Astrocytes:
The presence of tufted astrocytes is considered supportive but not required for the neuropathological diagnosis of PSP, as they are not present in all cases. [7]
Coiled bodies are oligodendroglial inclusions containing aggregated tau protein. They appear as argyrophilic, filamentous inclusions in the cytoplasm of oligodendrocytes, particularly affecting white matter tracts. These inclusions are a consistent finding in PSP and contribute to the white matter pathology observed in the disease.
Coiled Body Characteristics:
Thread-like inclusions represent distorted neuronal processes containing tau filaments, creating a "thread-like" appearance in affected brain regions. These tau-positive neurites are a major component of the pathological burden in PSP and contribute to synaptic dysfunction and neuronal disconnection. [8]
The brainstem is disproportionately affected in PSP, explaining many of the characteristic clinical features:
Substantia Nigra:
Superior Colliculus:
Oculomotor Nucleus (CN III):
Pontine Base:
Medullary Reticular Formation:
Globus Pallidus (interna and externa):
Subthalamic Nucleus:
Red Nucleus:
Thalamus:
Hypothalamus:
Compared to Alzheimer's disease, the cerebral cortex is relatively spared in PSP, though not entirely unaffected:
Motor Cortex (Brodmann area 4):
Prefrontal Cortex:
Primary Sensory Cortex:
PSP demonstrates remarkable regional specificity in neuronal loss, affecting specific populations while sparing others:
Most Vulnerable Neurons:
Relatively Spared:
Multiple mechanisms contribute to neuronal loss in PSP:
Astrocytosis is prominent in affected regions of PSP brains:
Astrocyte Activation:
Regional Distribution:
Microglial activation is consistently observed in PSP:
Activation Markers:
Functional Consequences:
Oligodendrocyte involvement in PSP includes:
Both PSP and CBD are classified as 4R tauopathies but have distinct neuropathological features:
| Feature | PSP | CBD |
|---|---|---|
| Astrocytic inclusions | Tufted astrocytes | Astrocytic plaques (cortico-basal) |
| Neuronal inclusions | NFTs in subcortex | NFTs in cortex |
| Cortical involvement | Moderate | Severe |
| Ballooned neurons | Rare | Characteristic |
| Microtubule pathology | Less prominent | Prominent |
| Distribution | Brainstem predominant | Cortical/subcortical |
The distinction can be challenging, and some cases show overlapping features, leading to the concept of "atypical" or "overlap" tauopathies. [9]
While both involve tau pathology, key differences include:
The National Institute of Neurological Disorders and Stroke (NINDS) and the Society for PSP (SPSP) established neuropathological diagnostic criteria:
Required Findings:
Supportive Findings:
Various staging systems have been proposed:
Braak Staging for PSP:
Common autopsy findings in PSP include:
Atrophy patterns:
Gross examination:
The balance between tau kinases and phosphatases is disrupted in PSP:
Kinases implicated:
Phosphatases implicated:
Tau aggregation in PSP involves:
Evidence supports prion-like spreading of tau pathology:
Neuropathological findings guide biomarker development:
Understanding neuropathology informs therapeutic development:
Tau Aggregation Inhibitors:
Anti-Tau Antibodies:
Gene Therapy:
The classic PSP phenotype (Richardson syndrome) correlates with maximum NFT burden in subthalamic nucleus and globus pallidus, severe brainstem involvement, and prominent tufted astrocytes. The characteristic "hummingbird" sign on MRI reflects midbrain atrophy. Patients present with the triad of vertical supranuclear gaze palsy, pseudobulbar palsy, and parkinsonism with axial rigidity. Neuropathologically, this variant shows the highest densities of NFTs in the brainstem and basal ganglia, with relative cortical sparing. The progression is typically more rapid than other PSP variants, with survival averaging 5-7 years from symptom onset. [10]
The parkinsonian variant (PSP-P) presents with more asymmetric parkinsonian features that may initially resemble idiopathic Parkinson's disease. Neuropathologically, PSP-P shows less severe brainstem involvement and greater cortical NFT burden compared to Richardson syndrome. This variant may show more significant involvement of the motor cortex and has been estimated to represent 20-30% of PSP cases. The clinical differentiation is important as PSP-P patients may initially respond to levodopa, while Richardson syndrome patients typically do not. Differentiation becomes clearer over time as vertical gaze palsy develops. [11]
PAGF represents a distinct clinical variant characterized by early gait freezing and akinesia without the classic supranuclear gaze palsy early in the disease course. Neuropathologically, PAGF shows minimal cortical involvement with predominant subcortical NFT burden. This variant typically has an earlier age of onset (mean ~58 years) and slower progression compared to Richardson syndrome. The neuropathological findings may be more focal, affecting primarily the globus pallidus and striatum. PAGF was initially described as a separate entity but is now recognized as part of the PSP spectrum. [11:1]
Some patients present with features of both PSP and corticobasal degeneration, reflecting overlapping neuropathology. This variant shows features of both 4R tauopathies, with astrocytic plaques typically found in CBD alongside tufted astrocytes characteristic of PSP. Cortical involvement is severe, and the clinical presentation includes asymmetric rigidity, apraxia, and cortical sensory loss. The distinction between PSP and CBD can be challenging both clinically and neuropathologically, and some cases are classified as "atypical" or "overlap" tauopathies. The existence of a unified CBD-PSP spectrum is supported by genetic studies showing shared risk alleles. [9:1]
The MAPT (Microtubule-Associated Protein Tau) gene located on chromosome 17q21.31 encodes the tau protein. The H1 haplotype, spanning the entire MAPT gene region, represents the major genetic risk factor for sporadic PSP. The H1/H1 genotype is associated with increased expression of 4R tau isoforms and significantly increases PSP risk (odds ratio ~3-5). This haplotype is also a risk factor for CBD and certain forms of FTD, supporting the concept of a shared 4R tauopathy spectrum. [12] [13]
The H2 haplotype appears protective, with reduced 4R tau expression. Interestingly, the H1 haplotype originated from a single founding event approximately 2,000 years ago and has since expanded in populations of European ancestry. The functional consequences of the H1 haplotype include:
While no specific mutations have been identified that cause PSP, several MAPT mutations cause related tauopathies:
These findings highlight the importance of tau metabolism in the pathogenesis of 4R tauopathies. [12:1]
Large GWAS have identified additional risk loci:
These findings suggest pathways beyond tau itself may contribute to PSP susceptibility, including myelin integrity and cellular stress responses. [13:1]
Several mouse models have been developed to study PSP pathophysiology:
P301S Tau Transgenic Mice:
4R Tau Overexpression Models:
AAV-Mediated Tau Expression:
Cell Culture Systems:
Organotypic Brain Slices:
Multiple therapeutic approaches are in various stages of clinical development:
Tau Aggregation Inhibitors:
Anti-Tau Immunotherapies:
Modulation Approaches:
Several factors complicate PSP therapeutic development:
Biomarker Limitations:
Patient Selection:
Trial Design:
Dickson DW et al. Neuropathology of variants of progressive supranuclear palsy. Acta Neuropathol. 2010. ↩︎
Litvan I et al. Prevalence of progressive supranuclear palsy. Neurology. 1996. ↩︎
Steele JC et al. Progressive supranuclear palsy. Arch Neurol. 1964. ↩︎
Goedert M et al. Tau isoforms and tau pathology. Trends Neurosci. 2000. ↩︎
Kovacs GG et al. Tauopathies. Acta Neuropathol. 2020. ↩︎
Braak H et al. Staging of brain pathology related to sporadic Parkinson disease. Neurobiol Aging. 2003. ↩︎
Saito Y et al. Tufted astrocytes in progressive supranuclear palsy. Acta Neuropathol. 2002. ↩︎
Duyckaerts C et al. Neuropathology of tauopathies. Acta Neuropathol. 2019. ↩︎
Dickson DW et al. Corticobasal degeneration and progressive supranuclear palsy. Neuropathology. 2008. ↩︎ ↩︎
Wider C et al. Progressive supranuclear palsy: clinicopathological concepts. Mov Disord. 2010. ↩︎
Williams DR et al. Tauopathies: classification and clinical update. Clin Neurosci. 2006. ↩︎ ↩︎
Hutton M et al. Molecular genetics of tauopathies. Nat Rev Neurosci. 2000. ↩︎ ↩︎
Baker M et al. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet. 1999. ↩︎ ↩︎